Study of LY4006895 for healthy people and those with early Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a body mass index (BMI) between 18 and 40.
- If you have Alzheimer's, you have had gradual memory problems for at least 6 months.
- If you have Alzheimer's, a memory test score is between 18 and 30, and a dementia rating is mild (0.5 to 1).
- If you have Alzheimer's, you have a reliable study partner who can join you for visits and talk by phone.
- You are not currently taking or have recently taken a treatment that targets amyloid plaques in the brain (for the Alzheimer's group).
- You do not have a serious medical condition that would make it unsafe to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This study tests a new drug called LY4405094 in healthy people and people with Alzheimer's disease. It aims to see if the drug is safe and how it works, but people with certain allergies (especially to adhesives) cannot join.
This study tests new treatments that target amyloid plaques in the brain, which are linked to Alzheimer's disease. It includes both healthy people and those with mild cognitive impairment or mild-to-moderate Alzheimer's, to see if the treatments are safe and how they affect the body.
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.